These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 22473769)

  • 21. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid biomarkers in Progranulin mutations carriers.
    Carecchio M; Fenoglio C; Cortini F; Comi C; Benussi L; Ghidoni R; Borroni B; De Riz M; Serpente M; Cantoni C; Franceschi M; Albertini V; Monaco F; Rainero I; Binetti G; Padovani A; Bresolin N; Scarpini E; Galimberti D
    J Alzheimers Dis; 2011; 27(4):781-90. PubMed ID: 21891865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
    Aisen PS; Saumier D; Briand R; Laurin J; Gervais F; Tremblay P; Garceau D
    Neurology; 2006 Nov; 67(10):1757-63. PubMed ID: 17082468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.
    Huey ED; Mirza N; Putnam KT; Soares H; Csako G; Levy JA; Copenhaver B; Cohen RM; Sunderland T
    Dement Geriatr Cogn Disord; 2006; 22(1):48-53. PubMed ID: 16682793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
    J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.
    Santos AN; Ewers M; Minthon L; Simm A; Silber RE; Blennow K; Prvulovic D; Hansson O; Hampel H
    J Alzheimers Dis; 2012; 29(1):171-6. PubMed ID: 22214781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
    Clark CM; Xie S; Chittams J; Ewbank D; Peskind E; Galasko D; Morris JC; McKeel DW; Farlow M; Weitlauf SL; Quinn J; Kaye J; Knopman D; Arai H; Doody RS; DeCarli C; Leight S; Lee VM; Trojanowski JQ
    Arch Neurol; 2003 Dec; 60(12):1696-702. PubMed ID: 14676043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
    Stomrud E; Hansson O; Zetterberg H; Blennow K; Minthon L; Londos E
    Arch Neurol; 2010 Feb; 67(2):217-23. PubMed ID: 20142530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.
    Seppälä TT; Nerg O; Koivisto AM; Rummukainen J; Puli L; Zetterberg H; Pyykkö OT; Helisalmi S; Alafuzoff I; Hiltunen M; Jääskeläinen JE; Rinne J; Soininen H; Leinonen V; Herukka SK
    Neurology; 2012 May; 78(20):1568-75. PubMed ID: 22517093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal changes of CSF biomarkers in memory clinic patients.
    Bouwman FH; van der Flier WM; Schoonenboom NS; van Elk EJ; Kok A; Rijmen F; Blankenstein MA; Scheltens P
    Neurology; 2007 Sep; 69(10):1006-11. PubMed ID: 17785669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Otto M; Kornhuber J; Rüther E; Wiltfang J
    Dement Geriatr Cogn Disord; 2011; 31(1):37-44. PubMed ID: 21135556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
    Le Bastard N; Martin JJ; Vanmechelen E; Vanderstichele H; De Deyn PP; Engelborghs S
    Neurobiol Aging; 2010 Nov; 31(11):1867-76. PubMed ID: 19150153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting.
    Dumurgier J; Vercruysse O; Paquet C; Bombois S; Chaulet C; Laplanche JL; Peoc'h K; Schraen S; Pasquier F; Touchon J; Hugon J; Lehmann S; Gabelle A
    Alzheimers Dement; 2013 Jul; 9(4):406-13. PubMed ID: 23141384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers.
    Slats D; Claassen JA; Spies PE; Borm G; Besse KT; van Aalst W; Tseng J; Sjögren MJ; Olde Rikkert MG; Verbeek MM
    Neurobiol Aging; 2012 Apr; 33(4):831.e1-9. PubMed ID: 21880396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
    Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid biomarkers of β-amyloid metabolism and neuronal damage in epileptic seizures.
    Shahim P; Rejdak R; Ksiazek P; Blennow K; Zetterberg H; Mattsson N; Rejdak K
    Eur J Neurol; 2014 Mar; 21(3):486-91. PubMed ID: 24372994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.